stock-detail (AGEN)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

EBCC-10 NEWS: Full Dose Radiotherapy To Whole Breast May Not Be Needed In Early Breast Cancer: First Results Of Local Recurrence In Women Participating In the IMPORT LOW TRIAL

3/9/2016 11:01 am

(ECCO) Mar 9, 2016 - Radiotherapy to the whole breast is standard treatment after breast-conserving surgery for women with early breast cancer, even those who have a low risk of the disease returning in the breast (local relapse).

Dietary Intervention Primes Triple-Negative Breast Cancer for Targeted Therapy

7/15/2015 11:03 am

(University of Wisconsin-Madison) July 14, 2015 - A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by a targeted antibody treatment, UW Carbone Cancer Center scientists report in a recent publication.

Mark Soloway, MD, Internationally Recognized Leader in Urologic Oncology, Joins Memorial Cancer Institute to Start New Division

7/18/2014 06:02 am

(PRWeb) July 17, 2014 - Dr. Mark Soloway, who has been appointed Chief of Urologic Oncology at Memorial Cancer Institute, will lead a new division focused on the care of bladder, prostate and kidney cancers, while also establishing a research program.

Promising Phase II Results for Agenus' Brain Cancer Vaccine

7/1/2014 06:02 am

(GEN) July 1, 2014 - The Phase II results are in for Agenus' autologous cancer vaccine Prophage: According to the immuno-oncology firm, the single-arm, multi-institutional, open-label study showed that patients with newly diagnosed glioblastoma multiforme (GBM) who received Prophage in addition to the standard of care treatment lived nearly twice as long as expected.

Agenus Brain Cancer Vaccine Nearly Doubles Survival Rate in Study

7/1/2014 01:05 am

(Reuters) July 1, 2014 - Agenus Inc said its experimental cancer vaccine helped brain tumor patients live nearly twice as long compared with those who received standard of care treatment.

GTx Reports Positive Clinical Data from Open Label Phase 2 Study of Enobosarm in Patients with Androgen and Estrogen Receptor Positive Metastatic Breast Cancer

6/2/2014 01:03 pm

(GTx) June 2, 2014 - GTx, Inc. today announced positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the treatment of patients with androgen receptor (AR) positive and estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormonal therapy.

Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer Immunotherapies

4/28/2014 12:01 pm

(Yahoo! Finance) Apr 28, 2014 - Agenus Inc. announced today that the company has entered into a collaboration and license agreement with Merck for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer.

Investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic Does Not Meet First Co-Primary Endpoints in MAGRIT, a Phase III Non-Small Cell Lung Cancer Clinical Trial

3/20/2014 07:00 am

(GlaxoSmithKline) Mar 20, 2014 - GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population.

Agenus Completes Acquisition of 4-Antibody

2/13/2014 12:00 pm

(Yahoo! Finance) Feb 13, 2014 - Agenus Inc., a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.

Agenus Announces Phase 2 Checkpoint inhibitor Combination Trial with Prophage Cancer Vaccine for Melanoma

1/14/2014 11:04 am

(MarketWatch) Jan 14, 2014 - Phase 2 randomized trial will study Yervoy® and Prophage combination for metastatic melanoma; first checkpoint inhibitor combination trial with Prophage vaccine.

Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG

1/13/2014 11:05 am

(Yahoo! Finance UK) Jan 13, 2014 - 4-Antibody has a powerful platform for rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets; lead programs target six immune checkpoint molecules; checkpoint antibodies have produced unprecedented results against a variety of cancers affecting a large number of patients; collaborations with the Ludwig Institute for Cancer Research and Memorial Sloan-Kettering Cancer Center.

Biomarker May Help Predict Aggressive Cancers

11/5/2013 11:04 am

(AACR) Nov 4, 2013 - For children with central nervous system cancers, the presence of a specific genetic modification—hypermethylation of the TERT promoter—may help predict tumor progression and patient survival, according to results presented at the AACR special conference on Pediatric Cancer at the Crossroads: Translating Discovery Into Improved Outcomes, held Nov. 3-6.

Agenus Brain Cancer Vaccine Improves Survival in Mid-Stage Study

9/17/2013 12:00 pm

(Reuters) Sep 17, 2013 - Biotechnology company Agenus Inc said its experimental brain cancer vaccine increased the survival of patients without their cancer worsening in a mid-stage trial, compared with the standard treatment.

Agenus Plunges After Partner Glaxo Reports Drug Trial Failure

9/5/2013 12:01 pm

(Bloomberg Businessweek) Sep 5, 2013 - Agenus Inc., a developer of treatments for cancer and infectious diseases, plummeted the most in four years after partner GlaxoSmithKline Plc’s (GSK) MAGE-A3 vaccine failed to help skin-tumor patients in a trial.

New York Tobacco Regulations Light Up Public Health Debate

5/2/2013 12:01 pm

(NPR) May 2, 2013 - If you're under 21, you may soon have a hard time lighting up in New York City. Public health officials in New York want to raise the minimum age for buying cigarettes.

Agenus Trial of Brain Cancer Vaccine Shows Better Survival Rate

5/2/2013 11:04 am

(Boston Business Journal) May 1, 2013 - Agenus Inc. on Wednesday reported results from a mid-stage trial of a potential brain cancer vaccine showing big increases in both progression-free and overall survival.

Ziopharm in Partner Talks for Experimental Cancer Drug

2/13/2013 12:03 pm

(BloombergBusinessweek) Feb 12, 2013 - Ziopharm Oncology Inc, a developer of experimental cancer drugs, is in talks with potential partners to market its lead compound, palifosfamide, Chief Executive Officer Jonathan Lewis said.

Distress Screening for Cancer Patients

12/13/2012 11:05 am

(ACCC Buzz) Dec 10, 2012 - The American College of Surgeons Commission on Cancer’s new Standard 3.2: Psychosocial Distress Screening continues to be a hot topic of discussion. Even a recent Wall Street Journal column, “To Treat the Cancer, Treat the Distress,” took note of the new mandate.

Op-Ed Column: A Possibly Fatal Mistake

10/15/2012 12:01 pm

(New York Times) Oct 12, 2012 - For all his innate prudence, Scott now, at age 52, is suffering from Stage 4 prostate cancer, in part because he didn’t have health insurance. President Obama’s health care reform came just a bit too late to help Scott, but it will protect others like him — unless Mitt Romney repeals it.

FDA Considers Faster Approval Process for Obesity Drugs

10/12/2012 11:00 am

(Bloomberg Businessweek) Oct 11, 2012 - Obesity treatments, life-saving antibiotics and other drugs deemed to offer societal benefit despite their risks may get speedier U.S. approvals under plans being discussed to better balance innovation and safety.

Agenus to Join Russell 3000 Index, Global Index, and MicroCap Index

6/18/2012 01:05 pm

[GlobeNewswire] - LEXINGTON, Mass. -- Agenus, Inc. , a biotechnology company working to develop treatments for cancers and infectious diseases, today announced that it is set to join the broad-market Russell 3000(R) Index, ...

Injectable Boniva Drug in Short Supply - US FDA

6/7/2012 12:04 pm

(Reuters) June 7, 2012 - Patients who want an injectable form of Roche Holding AG's bone-strengthening drug Boniva may not be able to get it in the next few weeks because the company did not accurately forecast demand, federal officials said.

Agenus to Webcast 2012 Annual Shareholders Meeting

6/1/2012 04:01 pm

[GlobeNewswire] - LEXINGTON, Mass. -- Agenus Inc. invites investors and the general public to its 2012 Annual Shareholders Meeting at 5:00 p.m. ET on Wednesday, June 13th. The meeting will be held at the company's headquarters ...

AGENUS INC Financials

5/17/2012 05:00 pm